Gilead Sciences is investing $250m in LEO Pharma’s preclinical small molecules. According to the deal, Gilead will develop oral versions of the potential inflammation drugs, while Denmark’s LEO will focus on topical versions. Additional payments of up to $1.7bn could go to LEO, depending on the research’s progress. The molecules are being developed to target IL-4 and IL-13 proteins, known to be linked to inflammation.
Sonatype reports rise in open source malware to 17,954
The 1Q 2025 Open Source Malware Index from Sonatype revealed that open source malware packages doubled compared to the same period last year, with 56%
